Co-led Atavistik Bio's $120M Series B financing alongside Nextech Invest to advance HHT and MPN programs.
Atavistik Bio is involved in the discovery and development of allosteric therapeutics within the biotechnology sector
Atavistik Bio is involved in the discovery and development of allosteric therapeutics within the biotechnology sector. The company has a drug discovery platform that identifies and targets allosteric binding pockets for the design of small molecule therapeutics. Atavistik Bio focuses on oncology and rare diseases, with a platform that addresses various target classes.